Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

Pseudomonas aeruginosa post-operative peritonitis: clinical features, risk factors, and prognosis.

Augustin P, Tran-Dinh A, Valin N, Desmard M, Crevecoeur MA, Muller-Serieys C, Woerther PL, Marmuse JP, Bronchard R, Montravers P.

Surg Infect (Larchmt). 2013 Jun;14(3):297-303. doi: 10.1089/sur.2012.084. Epub 2013 May 14.

PMID:
23672242
2.

Adjunctive rifampin is crucial to optimizing daptomycin efficacy against rabbit prosthetic joint infection due to methicillin-resistant Staphylococcus aureus.

Saleh-Mghir A, Muller-Serieys C, Dinh A, Massias L, Crémieux AC.

Antimicrob Agents Chemother. 2011 Oct;55(10):4589-93. doi: 10.1128/AAC.00675-11. Epub 2011 Aug 8.

3.

Development of a phenotypic method for detection of fecal carriage of OXA-48-producing enterobacteriaceae after incidental detection from clinical specimen.

Ruppé E, Armand-Lefèvre L, Lolom I, El Mniai A, Muller-Serieys C, Ruimy R, Woerther PL, Bilariki K, Marre M, Massin P, Andremont A, Lucet JC.

J Clin Microbiol. 2011 Jul;49(7):2761-2. doi: 10.1128/JCM.00055-11. Epub 2011 May 11.

4.

In vitro antibacterial activity of ceftobiprole against clinical isolates from French teaching hospitals: proposition of zone diameter breakpoints.

Lascols C, Legrand P, Mérens A, Leclercq R, Muller-Serieys C, Drugeon HB, Kitzis MD, Reverdy ME, Roussel-Delvallez M, Moubareck C, Brémont S, Miara A, Gjoklaj M, Soussy CJ.

Int J Antimicrob Agents. 2011 Mar;37(3):235-9. doi: 10.1016/j.ijantimicag.2010.11.035. Epub 2011 Feb 4.

5.

In vitro antibacterial activity of doripenem against clinical isolates from French teaching hospitals: proposition of zone diameter breakpoints.

Lascols C, Legrand P, Mérens A, Leclercq R, Armand-Lefevre L, Drugeon HB, Kitzis MD, Muller-Serieys C, Reverdy ME, Roussel-Delvallez M, Moubareck C, Lemire A, Miara A, Gjoklaj M, Soussy CJ.

Eur J Clin Microbiol Infect Dis. 2011 Apr;30(4):475-82. doi: 10.1007/s10096-010-1117-6. Epub 2010 Nov 19. Review.

6.

[Activity of doripenem against anaerobic bacteria].

Dubreuil L, Neut C, Mahieux S, Muller-Serieys C, Jean-Pierre H, Marchandin H, Soussy CJ, Miara A.

Pathol Biol (Paris). 2011 Apr;59(2):102-7. doi: 10.1016/j.patbio.2010.03.006. Epub 2010 May 26. French.

PMID:
20537808
7.

Emergence of carbapenem-resistant Hafnia: the fall of the last soldier.

Skurnik D, Nucci A, Ruimy R, Lasocki S, Muller-Serieys C, Montravers P, Andremont A, Courvalin P.

Clin Infect Dis. 2010 May 15;50(10):1429-31. doi: 10.1086/652289. No abstract available.

PMID:
20397936
8.

Comparative in vitro activity of Meropenem, Imipenem and Piperacillin/tazobactam against 1071 clinical isolates using 2 different methods: a French multicentre study.

Joly-Guillou ML, Kempf M, Cavallo JD, Chomarat M, Dubreuil L, Maugein J, Muller-Serieys C, Roussel-Delvallez M.

BMC Infect Dis. 2010 Mar 18;10:72. doi: 10.1186/1471-2334-10-72.

9.

Risk factors for multidrug resistant bacteria and optimization of empirical antibiotic therapy in postoperative peritonitis.

Augustin P, Kermarrec N, Muller-Serieys C, Lasocki S, Chosidow D, Marmuse JP, Valin N, Desmonts JM, Montravers P.

Crit Care. 2010;14(1):R20. doi: 10.1186/cc8877. Epub 2010 Feb 15.

10.

Development of ertapenem resistance in a patient with mediastinitis caused by Klebsiella pneumoniae producing an extended-spectrum beta-lactamase.

Skurnik D, Lasocki S, Bremont S, Muller-Serieys C, Kitzis MD, Courvalin P, Andremont A, Montravers P.

J Med Microbiol. 2010 Jan;59(Pt 1):115-9. doi: 10.1099/jmm.0.012468-0.

PMID:
19745032
11.

Rapid adaptation of antibiotic therapy for community-acquired peritonitis using direct cultures on antibiotic agar plates: pilot study.

Lasocki S, Skurnik D, Muller-Serieys C, Bronchard R, Marcel C, Marmuse JP, Montravers P, Andremont A.

Surg Infect (Larchmt). 2009 Aug;10(4):333-8. doi: 10.1089/sur.2008.095.

PMID:
19622030
12.

Bactericidal activity of the combination of levofloxacin with rifampin in experimental prosthetic knee infection in rabbits due to methicillin-susceptible Staphylococcus aureus.

Muller-Serieys C, Saleh Mghir A, Massias L, Fantin B.

Antimicrob Agents Chemother. 2009 May;53(5):2145-8. doi: 10.1128/AAC.01163-08. Epub 2009 Mar 9.

13.

Prospective evaluation of virulence factors of enterococci isolated from patients with peritonitis: impact on outcome.

Dupont H, Vael C, Muller-Serieys C, Chosidow D, Mantz J, Marmuse JP, Andremont A, Goossens H, Desmonts JM.

Diagn Microbiol Infect Dis. 2008 Mar;60(3):247-53. Epub 2007 Dec 3.

PMID:
18060725
14.

Activity of linezolid against Gram-positive cocci isolated in French hospitals as determined by three in-vitro susceptibility testing methods.

Muller-Serieys C, Drugeon HB, Etienne J, Lascols C, Leclercq R, Nguyen J, Soussy CJ.

Clin Microbiol Infect. 2004 Mar;10(3):242-6.

15.

Tissue kinetics of telithromycin, the first ketolide antibacterial.

Muller-Serieys C, Andrews J, Vacheron F, Cantalloube C.

J Antimicrob Chemother. 2004 Feb;53(2):149-57. Epub 2004 Jan 16. Review.

PMID:
14729764
16.

Emergence of resistance in normal human aerobic commensal flora during telithromycin and amoxicillin-clavulanic acid treatments.

Crémieux AC, Muller-Serieys C, Panhard X, Delatour F, Tchimichkian M, Mentre F, Andremont A.

Antimicrob Agents Chemother. 2003 Jun;47(6):2030-5.

17.

Activity and diffusion of tigecycline (GAR-936) in experimental enterococcal endocarditis.

Lefort A, Lafaurie M, Massias L, Petegnief Y, Saleh-Mghir A, Muller-Serieys C, Le Guludec D, Fantin B.

Antimicrob Agents Chemother. 2003 Jan;47(1):216-22.

18.

Predictive factors of mortality due to polymicrobial peritonitis with Candida isolation in peritoneal fluid in critically ill patients.

Dupont H, Paugam-Burtz C, Muller-Serieys C, Fierobe L, Chosidow D, Marmuse JP, Mantz J, Desmonts JM.

Arch Surg. 2002 Dec;137(12):1341-6; discussion 1347.

PMID:
12470095
19.

Combination of quinupristin-dalfopristin (Synercid) and rifampin is highly synergistic in experimental Staphylococcus aureus joint prosthesis infection.

Saleh-Mghir A, Ameur N, Muller-Serieys C, Ismael F, Lemaitre F, Massias L, Feger C, Bléton R, Crémieux AC.

Antimicrob Agents Chemother. 2002 Apr;46(4):1122-4.

20.

Intrapulmonary pharmacokinetics of telithromycin, a new ketolide, in healthy Japanese volunteers.

Kadota J, Ishimatsu Y, Iwashita T, Matsubara Y, Tomono K, Tateno M, Ishihara R, Muller-Serieys C, Kohno S.

Antimicrob Agents Chemother. 2002 Mar;46(3):917-21.

21.

[Blood culture update].

Muller-Serieys C, Bergogne-Bérézin E.

Presse Med. 2002 Jan 12;31(1 Pt 1):27-32. Review. French.

PMID:
11826583
22.

Multicenter evaluation of an automated system using selected bacteria that harbor challenging and clinically relevant mechanisms of resistance to antibiotics.

Leclercq R, Nicolas-Chanoine MH, Nordmann P, Philippon A, Marchais P, Buu-Ho A, Chardon H, Dabernat H, Doucet-Populaire F, Grasmick C, Legrand P, Muller-Serieys C, Nguyen J, Ploy MC, Reverdy ME, Weber M, Courcol RJ.

Eur J Clin Microbiol Infect Dis. 2001 Sep;20(9):626-35.

PMID:
11714043
23.

Bronchopulmonary disposition of the ketolide telithromycin (HMR 3647).

Muller-Serieys C, Soler P, Cantalloube C, Lemaitre F, Gia HP, Brunner F, Andremont A.

Antimicrob Agents Chemother. 2001 Nov;45(11):3104-8.

24.

An outbreak of imipenem-resistant Acinetobacter baumannii in critically ill surgical patients.

Fierobe L, Lucet JC, Decré D, Muller-Serieys C, Deleuze A, Joly-Guillou ML, Mantz J, Desmonts JM.

Infect Control Hosp Epidemiol. 2001 Jan;22(1):35-40.

PMID:
11198020
25.

[Ketolides and oxazolidinones. Mechanisms of action and antibacterial spectrum].

Muller-Serieys C.

Presse Med. 2000 Dec 2;29(37):2061-4. Review. French.

PMID:
11155736
26.

[Streptpcoccus pneumoniae: current status of its resistance to antibiotics].

Muller-Serieys C.

Presse Med. 2000 Dec 2;29(37):2057-60. Review. French.

PMID:
11155735
27.

[Epidemiology of resistance to antibiotics in respiratory tract infections].

Muller-Serieys C.

Presse Med. 1999 Nov 27;28 Suppl 3:37-42. Review. French.

PMID:
10605468
28.

Levofloxacin: serum bactericidal activity against methicillin-resistant Staphylococcus aureus isolates.

Muller-Serieys C, Decré D, Benoit C, Bigot C, Maubert B, Carbon C.

J Antimicrob Chemother. 1999 Jun;43 Suppl C:67-70.

PMID:
10404341
29.

[Bacterial resistance and new therapeutic perspectives].

Muller-Serieys C.

Presse Med. 1998 Dec;27 Suppl 5:42-6. French.

PMID:
9879336
30.

Pharmacokinetics of cefuroxime in healthy volunteers: an update.

Massias L, Muller-Serieys C, Farinotti R, Bergogne-Bérézin E.

J Antimicrob Chemother. 1998 Sep;42(3):408-10. No abstract available.

PMID:
9786491
31.

Dirithromycin concentrations in bronchial mucosa and secretions.

Leroyer C, Muller-Serieys C, Quiot J, Benhamou D, Clavier J, Bergogne-Bérézin E.

Respiration. 1998;65(5):381-5.

PMID:
9782221
32.

Native valve endocarditis due to Corynebacterium striatum: first reported case of medical treatment alone.

Tattevin P, Crémieux AC, Muller-Serieys C, Carbon C.

Clin Infect Dis. 1996 Dec;23(6):1330-1. No abstract available.

PMID:
8953092
33.

European multicentre evaluation of a commercial system for identification of methicillin-resistant Staphylococcus aureus.

Zambardi G, Fleurette J, Schito GC, Auckenthaler R, Bergogne-Berezin E, Hone R, King A, Lenz W, Lohner C, Makristhatis A, Marco F, Müller-Serieys C, Nonhoff C, Phillips I, Rohner P, Rotter M, Schaal KP, Struelens M, Viebahn A.

Eur J Clin Microbiol Infect Dis. 1996 Sep;15(9):747-9.

PMID:
8922577
34.

[In vitro antibacterial activity of a new fluoroquinolone, sparfloxacin, against nosocomial bacteria, and concordance curve].

Soussy CJ, Cluzel M, Derlot E, Exmelin L, Kitzis MD, Dabernat H, Le Noc P, Muller-Serieys C, Reverdy ME, Scheftel JM, Thabaut A.

Pathol Biol (Paris). 1996 Apr;44(4):241-8. French.

PMID:
8763585
35.

Activity of beta-lactamase inhibitor combinations on Escherichia coli isolates exhibiting various patterns of resistance to beta-lactam agents.

Vanjak D, Muller-Serieys C, Picard B, Bergogne-Berezin E, Lambert-Zechovsky N.

Eur J Clin Microbiol Infect Dis. 1995 Nov;14(11):972-8.

PMID:
8654448
36.

Penetration of piperacillin-tazobactam into bronchial secretions after multiple doses to intensive care patients.

Jehl F, Muller-Serieys C, de Larminat V, Monteil H, Bergogne-Berezin E.

Antimicrob Agents Chemother. 1994 Dec;38(12):2780-4.

37.

Concentration of meropenem in serum and in bronchial secretions in patients undergoing fibreoptic bronchoscopy.

Bergogne-Bérézin E, Muller-Serieys C, Aubier M, Dombret MC.

Eur J Clin Pharmacol. 1994;46(1):87-8. Erratum in: Eur J Clin Pharmacol 1994;46(3):282.

PMID:
8005193
38.

[Mixed pneumopathies caused by Neisseria meningitidis associated with other bacteria].

Gérard B, Muller-Serieys C, Aubier M, Bergogne-Bérézin E, Riou JY.

Presse Med. 1992 Dec 19-26;21(44):2151. French. No abstract available.

PMID:
1297133
39.

Penetration of cefpodoxime proxetil in lung parenchyma and epithelial lining fluid of noninfected patients.

Muller-Serieys C, Bancal C, Dombret MC, Soler P, Murciano G, Aubier M, Bergogne-Berezin E.

Antimicrob Agents Chemother. 1992 Oct;36(10):2099-103.

40.

Penetration of lomefloxacin into bronchial secretions following single and multiple oral administration.

Bergogne-Bérézin E, Muller-Serieys C, Kafé H.

Am J Med. 1992 Apr 6;92(4A):8S-11S.

PMID:
1316076
41.

[Role of cefuroxime-axetil in the treatment of respiratory tract infections. Bacteriological and pharmacological data].

Bergogne-Berezin E, Vallée E, Muller-Serieys C.

Therapie. 1991 Jul-Aug;46(4):333-7. French.

PMID:
1948811
42.

[From the parenchyma to the mucosa biopsy: significance and importance of local assays of antibiotics. A critical study].

Bergogne-Berezin E, Muller-Serieys C.

Rev Mal Respir. 1990;7(6):551-7. Review. French.

PMID:
2270342
43.

[In vitro antibacterial effect of a new oral cephalosporin, cefixime. Results of a multicenter study].

Soussy CJ, Kitzis MD, Thabaut A, Chanal M, Bure A, Vergnaud M, Reynaud AE, Coulet M, Dabernat H, Muller-Serieys C, et al.

Pathol Biol (Paris). 1989 Jun;37(5 Pt 2):528-33. French.

PMID:
2508039
44.

[Nosocomial infections caused by Acinetobacter. Epidemiology and therapeutic difficulties].

Muller-Serieys C, Lesquoy JB, Perez E, Fichelle A, Boujeois B, Joly-Guillou ML, Bergogne-Berezin E.

Presse Med. 1989 Jan 28;18(3):107-10. French.

PMID:
2521935
45.

Imipenem penetration into bronchial secretions.

Muller-Serieys C, Bergogne-Berezin E, Rowan C, Dombret MC.

J Antimicrob Chemother. 1987 Oct;20(4):618-9. No abstract available.

PMID:
3479422
46.

[Present status of nitroxoline].

Bergogne-Berezin E, Berthelot G, Muller-Serieys C.

Pathol Biol (Paris). 1987 Jun;35(5 Pt 2):873-8. Review. French.

PMID:
3309832
47.

[Fosfomycin-trometamol (monuril): pharmacokinetics and food-drug interactions].

Muller-Serieys C, Bergogne-Berezin E, Joly-Guillou ML.

Pathol Biol (Paris). 1987 Jun;35(5 Pt 2):753-6. French.

PMID:
3309810
48.

Study of the penetration of imipenem into the bronchial secretions.

Muller-Serieys C, Bergogne-Berezin E, Rowan C, Dombret M, Besse S.

Chemioterapia. 1987 Jun;6(2 Suppl):260-1. No abstract available.

PMID:
3151344
49.

Trometamol-fosfomycin (Monuril) bioavailability and food-drug interaction.

Bergogne-Bérézin E, Muller-Serieys C, Joly-Guillou ML, Dronne N.

Eur Urol. 1987;13 Suppl 1:64-8.

PMID:
3569381

Supplemental Content

Loading ...
Support Center